Irhythm Technologies AI Stock Analysis
Irhythm Technologies (0A7L) AI Stock Analysis
Irhythm Technologies
(LSE:0A7L)
No summary available
Irhythm Technologies (0A7L) vs. iShares MSCI United Kingdom ETF (EWC)
- Market Cap
- $3.17B
- Dividend Yield
- ―
- Average Volume (3M)
- 122
- Price to Earnings (P/E)
- -80.5
- Beta (1Y)
- 0.82
- Revenue Growth
- 21.56%
- EPS Growth
- 27.87%
- Country
- UK
- Employees
- 2,400
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Devices
Irhythm Technologies Business Overview & Revenue Model
Company Description
iRhythm Holdings, Inc., a digital healthcare company, engages in the design, development, and commercialization of device-based technology that provides ambulatory cardiac monitoring services to diagnose arrhythmias in the United States. The company...
Irhythm Technologies Earnings Call Summary
The call was predominantly positive, supported by 14.9% revenue growth, record adjusted EBITDA profitability, improved adjusted net income, strong underlying cash generation, raised 2026 guidance, and the strategic expansion from VitalConnect. The main negative factors were flat Zio AT revenue, near-term customer onboarding delays, the postponement of the Zio MCT FDA filing to 2027, the GAAP loss and negative reported free cash flow caused by the litigation settlement, and ongoing regulatory and market-access work. Highlights significantly outweighed the lowlights, although management acknowledged near-term uncertainty in the MCT transition.
Q3-2026 Updates
Positive Updates
Negative Updates
Company Guidance
Management raised full year 2026 revenue guidance to $890 million to $895 million, representing 19% to 20% year-over-year growth, assuming Zio Monitor year-over-year growth of mid-teens in Q4, approximately $16 million of VitalConnect revenue in Q4, and Zio AT sequentially flat to Q3; Zio AT is expected to be down about 10% on a dollar basis and flat year-over-year on a volume basis in Q4. Organic iRhythm gross margin is expected to remain generally consistent with third quarter levels, excluding the onetime benefit associated with tariff refunds, with total company gross margin above 70% in the fourth quarter, while full year adjusted EBITDA margin guidance was raised to 15.5% to 16%; excluding certain onetime items, free cash flow is expected to increase year-over-year in 2026, with positive free cash flow generation in the fourth quarter. For 2027, the organic iRhythm business is expected to track toward approximately $1 billion in revenue, with Zio Monitor growth in the mid-teens, Zio AT flat versus 2026, and VitalConnect growth slightly above organic iRhythm growth, or mid to high teens, relative to the $65 million run rate in 2026; the company expects gross margin above 70% and an adjusted EBITDA margin of at least 15%.
Irhythm Technologies Risk Analysis
Irhythm Technologies disclosed 126 risk factors in its most recent earnings report. Irhythm Technologies reported the most risks in the "Finance & Corporate" category.
Latest Risks Added
3 New RisksIrhythm Technologies Peers Comparison
Overall Rating
MDT81Outperform
GEHC79Outperform
ABT67Neutral
PHG67Neutral
BSX64Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 81Outperform | $128.70B | 24.66 | 10.60% | 2.84% | 9.77% | 12.28% | |
| 79Outperform | $37.03B | 17.28 | 19.85% | 0.18% | 6.87% | -2.26% | |
| 67Neutral | $179.90B | 38.51 | 9.11% | 2.43% | 10.00% | -66.06% | |
| 67Neutral | $28.53B | 26.57 | 8.44% | 3.38% | ― | ― | |
| 64Neutral | $62.31B | 18.14 | 13.87% | ― | 8.88% | 25.77% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| GB:0A7L | Irhythm Technologies | 97.00 | -82.66 | -46.01% | |
| ABT | Abbott Laboratories | 103.87 | -21.13 | -16.91% | |
| BSX | Boston Scientific | 42.99 | -53.89 | -55.63% | |
| PHG | Koninklijke Philips N.V. | 29.25 | 2.86 | 10.84% | |
| MDT | Medtronic | 100.61 | 2.66 | 2.71% | |
| GEHC | Ge Healthcare Technologies Inc. | 81.89 | 5.59 | 7.33% |
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
